Recent reports suggest that human immunodeficiency virus (HIV) -associated progressive multifocal leukoencephalopathy (PML) may improve with highly active antiretroviral therapy (HAART). We observed three patients who developed PML while receiving HAART. All patients received HAART for 4-11 months and had low plasma levels of HIV-1 RNA before the onset of symptoms of PML. Antiretroviral therapy was changed in two patients, and their plasma HIV-1 RNA levels declined significantly. Despite this virologic response, PML did not improve in these patients. The third patient's HIV-1 RNA level became undetectable while he was receiving HAART, and his symptoms of PML improved after the addition of interferon a. Our observations suggest that PML can develop in patients who have shown clinical response to HAART. Furthermore, PML may not improve despite an adequate virologic response to HAART. Definitive therapy is still needed for PML.
Progressive multifocal leukoencephalopathy (PML) is an intwice daily. Two months later, the plasma HIV-1 RNA level was 409 copies/mL and his CD4 / lymphocyte count was fection of the white matter of the CNS that is usually fatal. There is no proven curative treatment [1] . Recent case series 656/mm 3 . Despite the immunologic and virologic improvement, the patient had neurological deterioration and died 2 of HIV-associated PML suggest that protease inhibitor -based highly active antiretroviral therapy (HAART) may lengthen months later. survival and improve neurological outcome [2 -8] . Recently, Case 2. A 45-year-old man presented with several weeks we observed three patients with PML that developed in the of frontal headaches, grand mal seizures, diplopia, and blurred presence of HAART.
vision. He was initially treated with zidovudine, 200 mg three times daily; lamivudine, 150 mg twice daily; and indinavir, 800 mg three times daily. His plasma HIV-1 RNA level was Case Reports 27,522 copies/mL when this therapy was begun. Zidovudine Case 1. A 51-year-old man presented with dysarthria and was changed to stavudine, 40 mg twice daily, because of the weakness of the left arm and leg. One year prior, the patient patient's intolerance to zidovudine. A plasma HIV-1 RNA began taking stavudine, 40 mg twice daily; lamivudine, 150 measurement done 8 months into therapy was 1,803 copies/ mg twice daily; and saquinavir soft-gel, 600 mg three times mL and his CD4 / lymphocyte count was 100/mm 3 . One daily. One month later, the patient's plasma HIV-1 RNA level month later, he noted the onset of frontal headaches and then was 8,003 copies/mL and his CD4 / lymphocyte count was had two grand mal seizures followed by diplopia and blurred 175/mm 3 . Eleven months later, the patient developed weakvision. MRI of the brain revealed a new ring enhancing lesion ness of the right upper and lower extremities and dysarthria.
of the left parietal lobe that showed PML on histologic analy-MRI of the brain showed nonenhancing lesion of the left sis. At diagnosis, his plasma HIV-1 RNA level was 4,047 cerebellar hemisphere. CSF testing by PCR showed positive copies/mL and his CD4 / lymphocyte count was 36/mm 3 . results for JC virus. The antiretroviral regimen was changed Antiretroviral treatment was changed to didanosine, 200 mg to didanosine, 200 mg twice daily; lamivudine, 150 mg twice twice daily; nevirapine, 200 mg twice daily; ritonavir, 400 daily; indinavir, 800 mg thrice daily; and nevirapine, 200 mg mg twice daily; and saquinavir, 400 mg twice daily. The HIV-1 RNA decreased to undetectable levels and his CD4 / lymphocyte count rose to 201/mm 3 within 2 months. However, the neurological symptoms continued, and he died 1 navir, 800 mg three times daily. His CD4 / lymphocyte count There may be several reasons why PML can develop and/or progress despite the use of HAART. Clearly, nonadherwas 450/mm 3 , and his plasma HIV-1 RNA level was 206,659 copies/mL before initiation of treatment. After a 2-month inence to HAART is one possibility. Our patients had detectable levels of HIV before the diagnosis of PML, which is suggestive terruption in therapy because of gastrointestinal side effects, he began taking stavudine, 40 mg twice daily; lamivudine, of suboptimal adherence. However, adherence after the diagnosis of PML was good, since each of our patients had a virologic 150 twice daily; saquinavir, 400 mg twice daily; and ritonavir, 400 mg twice daily. After 8 weeks, his plasma HIV-1 RNA and immunologic response temporally associated with the use of antiretrovirals. Another possible explanation is that PML level was 2,593 copies/mL. One month later, he developed blurred vision and progressive weakness of the extremimay develop in patients with a previously established CNS infection with JC virus that antedates treatment with HAART. ties. MRI of the brain revealed a right parietal lobe lesion involving the white matter. Analysis of CSF by PCR yielded
In this scenario, PML would develop regardless of any subsequent virologic response to HAART. This phenomenon has positive results for JC virus. IFN-a, 3 1 10 6 U three times weekly, was added to his antiretroviral regimen. Gradually been described for other opportunistic illnesses in patients recently initiating HAART [10] . It is also possible that specific his vision and weakness improved. Two months later his vision was normal, his CD4
/ lymphocyte count was 550/mm 3 , protective immunologic defenses directed against JC virus may be irrevocably lost in some patients with advanced HIV infecand his plasma HIV-1 RNA level was 444 copies/mL. One month later, his plasma HIV-1 RNA declined to undetectable tion. Loss of specific clonal populations of immune effector cells may occur during the course of HIV-1 infection. Regenerlevels (õ400 copies/mL).
ation of these clonal populations in sufficient numbers (or levels of activity) may not be possible after the initiation of HAART.
Discussion
Last, some strains of JC virus may also be more virulent. It may be that some combination of these factors is necessary for PML is a devastating disease that is usually fatal in advanced HIV infection. There have been a number of case reports of the development or progression of PML despite the use of HAART. Further delineation of the pathogenesis of PML is agents with putative efficacy against PML [1]. However, there are no controlled studies demonstrating curative therapy for needed.
In conclusion, it appears that PML can develop in AIDS PML. Recently, there have been several reports of improvement in PML with treatment with HAART that usually includes a patients and progress despite adequate virologic responses to protease inhibitor -based HAART. Studies are needed to improtease inhibitor [2 -8] . In an ongoing prospective observational study of PML, the use of HAART was associated with prove our understanding of the pathogenesis of PML and the pathogen-specific immunity for JC virus. Development of spea median survival of ú12 months, compared with survival of õ4 months without treatment [4] . Gasnault et al. [5] similarly cific treatment for PML may still be required. reported a median survival of 15.5 months with the use of HAART in patients with AIDS-related PML. In the absence of any proven curative therapy, HAART is currently considered HAART, both of whom had very low HIV-1 RNA levels.
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